<DOC>
	<DOCNO>NCT00985907</DOCNO>
	<brief_summary>The median overall survival ( OS ) relapsed/refractory multiple myeloma ( MM ) less nine month . However , phase II data proteasome inhibitor bortezomib ( Velcade® ) heartening , 35 % overall response rate median survival 16 month . In-vitro data show agent dramatically increase sensitivity chemotherapeutic agent . Liposomal doxorubicin ( Doxil ) , melphalan , bortezomib different mechanism action toxicity profile . Clinical study employ two drug combination agent patient refractory MM find favorable efficacy ( nearly progression disease ) tolerance data . Thus , investigator initiate phase I/II study examine safety efficacy combine three agent regimen DMV ( Doxil® + melphalan + Velcade ) .</brief_summary>
	<brief_title>Doxil® + Melphalan + Velcade ( DMV ) Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>Dose Level 1 : Doxil 10 mg/m2 , Melphalan 5 mg/m2 , Velcade 0.7 mg/m2 Dose Level 2 : Doxil 10 mg/m2 , Melphalan 10 mg/m2 , Velcade 0.7 mg/m2 Dose Level 3 : Doxil 20 mg/m2 , Melphalan 10 mg/m2 , Velcade 0.7 mg/m2 Dose Level 4 : Doxil 20 mg/m2 , Melphalan 10 mg/m2 , Velcade 1.0 mg/m2 Adjunctive therapy bisphosphonate , either pamidronate zolendronic acid , give monthly . Dose Escalation Schedule : Dose escalation occur patient complete least two cycle give dose level . 1 . If 0/3 experience DLT ( define attachment Section 6.0 ) , next three patient escalate one dose level . 2 . If 1/3 experience DLT , 3 additional patient enrol dose level . - If 0 , 1 , 2 additional patient experience DLT ( i.e . total 3/6 ) , dose escalate . - If 3/3 experience DLT ( i.e . total 4/6 ) next low dose consider MTD.. 3 . If 2/3 experience DLT , 3 additional patient enrol dose level . - If 0 1 additional patient experience DLT ( i.e . total 3/6 ) , dose escalate . - If 2 more/3 experience DLT ( i.e . total 3/6 ) next low dose level MTD</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Disease Characteristics : 1 . Patient previously diagnose MM ; 2 . Progressive disease . For nonsecretory multiple myeloma , progressive disease define bone marrow biopsy &gt; 25 % increase plasma cell absolute increase least 10 % prior know level . Alternatively , development new worsen exist lytic bone lesion soft tissue plasmacytoma , hypercalcemia ( serum calcium &gt; 11.5 mg/dL ) , relapse CR . Patient Characteristics : 1 . 18 yrs old 2 . Patient give voluntary write informed consent . 3 . Unless postmenopausal surgically sterilize , female must willing use acceptable method birth control 4 . Male patient must agree use acceptable method contraception duration study . 5 . ECOG Performance Status 02 . 6 . Life expectancy least 3 month . 7 . • ANC 1,000/ul without use colony stimulate factor Platelets 50,000/ul without transfusion support 7 day Bilirubin 2.0 mg/dl less AST 4 time less upper limit normal Prior Therapy Multiple Myeloma : Patients must least 2 prior therapeutic regimen Pregnant breast feed History allergic reaction compound contain boron mannitol . Active uncontrolled viral ( include HIV ) , bacterial , fungal infection . Grade III IV toxicity due previous antineoplastic therapy More Grade 2 motor sensory neuropathy MI within 6 month enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled arrhythmia , electrocardiographic evidence acute ischemia . For patient whose lifetime cumulative doxorubicin dose exceeds 400mg/m2 , patient LVEF le 35 % MUGA . Concurrent administration liposomal doxorubicin , melphalan , bortezomib ( single two drug combination permissible ) Less 3 week since recent chemotherapy concurrent chemotherapy Use corticosteroid ( mroe 10 mg prednisone/day equivalent )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>myeloma</keyword>
	<keyword>DMV</keyword>
</DOC>